C-EHYLMogrify
direct cellular reprogramming, epigenetics, transcription factors
reprogrammingepigenetic reprogramming
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-EHYL
C-EHYLC-EHYLdirect cellular reprogramming, epigenetics, transcription factors
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Mogrify direct cellular reprogramming, epigenetics, transcription factors
Mogrify is developing a novel class of in vivo reprogramming therapies for indications including otology, ophthalmology, diabetes, and other high-unmet-need disease areas. Its proprietary MOGRIFY and epiMOGRIFY platforms use transcriptomic, epigenetic, gene regulatory, and sequencing data to identify factors that can convert or maintain cell identity. The company aims to recover cell types lost through disease or injury to restore organ function directly in situ.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Mogrify — Early mechanism · Lower middle. Derived deterministically from 6 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (3 programs at preclinical).…
Source: Deterministic